Bone Fragility in Turner Syndrome: Mechanisms and Prevention Strategies
- PMID: 27199891
- PMCID: PMC4844601
- DOI: 10.3389/fendo.2016.00034
Bone Fragility in Turner Syndrome: Mechanisms and Prevention Strategies
Abstract
Bone fragility is recognized as one of the major comorbidities in Turner syndrome (TS). The mechanisms underlying bone impairment in affected patients are not clearly elucidated, but estrogen deficiency and X-chromosomal abnormalities represent important factors. Moreover, although many girls with TS undergo recombinant growth hormone therapy to treat short stature, the efficacy of this treatment on bone mineral density is controversial. The present review will focus on bone fragility in subjects with TS, providing an overview on the pathogenic mechanisms and some prevention strategies.
Keywords: Turner syndrome; bone; bone mineral density; estrogens; fractures.
Figures
References
-
- Gravholt CH, Lauridsen AL, Brixen K, Mosekilde L, Heickendorff L, Christiansen JS. Marked disproportionality in bone size and mineral, and distinct abnormalities in bone markers and calcitropic hormones in adult Turner syndrome: a cross-sectional study. J Clin Endocrinol Metab (2002) 87:2798–808. 10.1210/jcem.87.6.8598 - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
